With novel disease modifying therapeutic products NsGene targets neurological diseases with great medical need. NsGene's proprietary EC BiodeliveryTM technology is capable of delivering therapeutic proteins to the CNS and NsGene’s proprietary therapeutic proteins can be delivered systemically to the PNS. This creates a potential for symptomatic and potentially curative treatments of patients that today have no chance of cure. NsGene products are aimed at the world market.
Market Growth
The overall market for current treatments of nervous system disorders is valued in excess of 75 billion US dollars in 2010. The leading indications that NsGene is focusing on have a global market around 10 billion US dollars, expected to double by 2020.
NsGene is focusing on neurological indications with approximately 40 million patients in Western Europe, USA, and Japan. Today, there are no comparable products to NsGene's product candidates on the market. Therefore market penetration is expected to be rapid and significant and the products competitive.
